Roche says EU regulator panel backs Susvimo approval for wet AMD
EU panel recommends Susvimo for neovascular age-related macular degeneration
EU drug regulator CHMP recommended approval of Roche’s Susvimo for neovascular age-related macular degeneration, paving the way for a European Commission decision.
Implant-based delivery is positioned as an alternative to frequent injections
Susvimo uses the Contivue refillable eye implant to continuously deliver ranibizumab, positioned as an alternative to frequent anti-VEGF injections.
Trial data showed comparable vision outcomes and limited need for supplemental treatment
Archway, LADDER, Portal data showed vision outcomes comparable to monthly ranibizumab injections; about 95% needed no supplemental anti-VEGF with two refills yearly.
